ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
 > Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
ACC: GLP-1 Analog Use Cuts Heart Failure Events in Diabetes
Use of glucagon-like peptide 1 analogs tied to reduced risk of heart failure hospitalization

MONDAY, March 11 (HealthDay News) -- For adults with diabetes, use of glucagon-like peptide 1 (GLP-1) analogs is associated with a reduced risk of heart failure hospitalization, all-cause hospitalization, and all-cause mortality, according to a study presented at the annual meeting of the American College of Cardiology, held from March 9 to 11 in San Francisco.

Noting that recent studies suggest GLP-1 agents may be protective against heart failure, David Lanfear, M.D., from Henry Ford Hospital in Detroit, and colleagues conducted a retrospective cohort study involving adults with diabetes from a large health system in southeast Michigan. The effect of GLP-1 agents on time to heart failure hospitalization, all-cause hospitalization, and all-cause mortality was assessed for 1,488 new users of GLP-1 agents and 2,939 propensity-matched controls.

Over a median observation period of 663 days, the researchers identified 281 hospitalizations, of which 184 were attributed to heart failure, and 158 deaths. Use of GLP-1 agents correlated with a significantly reduced risk of heart failure hospitalization, all-cause hospitalization, and all-cause mortality (adjusted hazard ratios, 0.56, 0.56, and 0.20, respectively).

"These preliminary results look very promising," Lanfear said in a statement. "However, this was a retrospective study and this subject needs further investigation."

More Information



Health News Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS